Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

Imagem de Miniatura
Arquivos
art_CERQUEIRA-SILVA_Influence_of_age_on_the_effectiveness_and_duration_2022.PDF (657.56 KB)
Citações na Scopus
51
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
CERQUEIRA-SILVA, Thiago
OLIVEIRA, Vinicius de Araujo
BOAVENTURA, Viviane S.
PESCARINI, Julia M.
JUNIOR, Juracy Bertoldo
MACHADO, Tales Mota
FLORES-ORTIZ, Renzo
PENNA, Gerson O.
ICHIHARA, Maria Yury
Citação
LANCET REGIONAL HEALTH-AMERICAS, v.6, article ID 100154, 11p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Aging influences COVID-19 severity and response to vaccination, but previous vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within the elderly age group. Here we analyzed the impact of age on viral vector and inactivated virus vaccines' effectiveness, the main platforms used in low- and middle-income countries. Methods We report a retrospective longitudinal study of 75,919,840 Brazilian vaccinees from January 18 to July 24, 2021, evaluating documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19-related hospitalisation, ICU admission, and death. Negative binomial regression models adjusted for sociodemographic characteristics were used for VE estimation. Findings The overall analyzes of full vaccination showed VE against hospitalisation, ICU admission, and death of 91 center dot 4% (95%CI:90 center dot 1-92 center dot 5), 91 center dot 1% (95%CI:88 center dot 9-92 center dot 9) and 92 center dot 3% (95%CI:90 center dot 5- 93 center dot 7) for Vaxzevria and 71 center dot 2% (95%CI:70 center dot 0-72 center dot 4), 72 center dot 2% (95%CI:70 center dot 2-74 center dot 0) and 73 center dot 7% (95%CI:72 center dot 1-75 center dot 2) for CoronaVac, respectively. VE for all outcomes is progressively lower with age. In fully-Vaxzevria-vaccinated individuals aged < 60 years, VE against death was 96.5% (95%CI:82.1- 99.3) versus 68 center dot 5% (95%CI:40 center dot 0-83 center dot 4) in those >= 90 years. Among fully-CoronaVac-vaccinated individuals, VE against death was 84.8% (95%CI:77.1- 89.9) in those < 60 years compared to 63.5 (95%CI 58.7-67.7) for vaccinees aged 80-89 years and 48 center dot 6%; (95%CI:35 center dot 0-59 center dot 3) for individuals aged >= 90 years. Post-vaccination daily cumulative incidence curves for all outcomes showed increased risk from younger to elder decades of life. There was no increase in the incidence of hospitalisation for individuals <60 years vaccinated during the same period as those aged >= 90 years. Interpretation Although both vaccines have been effective in protecting against infection, hospitalization and death; Vaxzevria and CoronaVac demonstrated high effectiveness against severe outcomes for individuals up to 79 years of age. Our results reinforce the idea that booster doses should be carefully considered in elders. Funding This study was partially supported by a donation from the ""Fazer o bem faz bem"" program.
Palavras-chave
COVID-19, Vaccine, Effectiveness, CoronaVac, Vaxzevria
URI
https://observatorio.fm.usp.br/handle/OPI/51662
Referências
  1. Allik Mirjam, 2020, ERD, DOI 10.5525/GLA.RESEARCHDATA.980
  2. [Anonymous], 2021, PLAN NAC OP VAC COVI
  3. Aquino EML, 2020, CIENC SAUDE COLETIVA, V25, P2423, DOI 10.1590/1413-81232020256.1.10502020
  4. Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891
  5. Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088
  6. Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985
  7. Chodick G, 2022, CLIN INFECT DIS, V74, P472, DOI 10.1093/cid/ciab438
  8. Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943
  9. Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
  10. Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
  11. Frater J, 2021, LANCET HIV, V8, pE474, DOI 10.1016/S2352-3018(21)00103-X
  12. Hitchings MDT., 2021, MEDRXIV
  13. Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715
  14. Lima Francisca Elisângela Teixeira, 2021, Epidemiol. Serv. Saúde, V30, pe2020788, DOI [10.1590/S1679-4974202100010002, 10.1590/s1679-4974202100010002]
  15. Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214
  16. Moghadas SM, 2021, CLIN INFECT DIS, V73, P2257, DOI 10.1093/cid/ciab079
  17. Oliveira EA, 2021, LANCET CHILD ADOLESC, V5, P559, DOI 10.1016/S2352-4642(21)00134-6
  18. Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
  19. Pietrobon AJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579220
  20. R Core Team (2015), 2015, R LANG ENV STAT COMP
  21. Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015
  22. Ranzani OT, 2021, LANCET RESP MED, V9, P407, DOI 10.1016/S2213-2600(20)30560-9
  23. Rede Gen^omica Fiocruz, DASHB RED GEN GEN FI
  24. da Silva SJR, 2021, ONE HEALTH-AMSTERDAM, V13, DOI 10.1016/j.onehlt.2021.100287
  25. Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z
  26. Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1
  27. Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X
  28. Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2
  29. Victora C, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101036
  30. Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3
  31. Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/01
Artigos e Materiais de Revistas Científicas - ODS/03